Advertisement

Relevance of Dopaminergic Agonists and Antagonists to Parkinsonian Tremor

  • S. Ruggieri
  • A. Denaro
  • M. Baldassarre
  • F. Stocchi
  • A. Agnoli
Conference paper

Abstract

Tremor is the most complex symptom of Parkinson’s disease, either for physiopathology or for neurochemistry. It seems to be the result of a derangement of cortical-subcortical loops which in Parkinson’s disease also involve the nigrostriatal system (Poirier et al. 1976; Teravainen et al. 1979; Narabayashi et al. 1979). Furthermore, in tremor there are very complex modifications of neurotransmitters which cause the onset of this symptom through a derangement of the relationship of the neurotransmitters themselves (Barbeau 1962; McGeer et al. 1961; Siegfrid 1976). The nigrostriatal dopaminergic system is certainly involved in the pathogenesis of tremor, even if a clear relationship between tremor and the damage of the dopaminergic system does not exist (Rinne et al. 1982).

Keywords

Ergot Alkaloid Parkinsonian Tremor Dopa Decarboxylase Inhibitor Parkinsonism Tremor Short Feedback Loop 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agnoli A, Ruggieri S, Casacchia M (1978) Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry. Pharmacology (Suppl 1) 16: 174–188PubMedCrossRefGoogle Scholar
  2. Agnoli A, Baldassarre M, del Roscio S, Palesse N, Ruggieri S (1981) Piribedil and Parkinson’s disease: Protection of peripheral side effects by Domperidon. In: Corsini G, Gessa GL (eds) Apomorphin and other dopaminomimetics. Raven, New York, pp 117–122Google Scholar
  3. Agnoli A, Ruggieri S, Baldassarre M, Stocchi F, Denaro A, Falaschi P (1983) Basic mechanisms and endocrine and neurological effects. In: Calne DB, Donald B, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 407–417Google Scholar
  4. Barbeau A (1962) The pathogenesis of Parkison’s disease: a new hypothesis. Can Med Ass J 87: 802–807PubMedGoogle Scholar
  5. Berde B (1980) Ergot compounds: a synopsis. In: Goldstein M, Calne DB, Lieberman A, Thorner MO (eds) Advances in biochemical psychopharmacology, vol 23. Raven, New York, pp 3–24Google Scholar
  6. Calne DB (1982) Dopamine agonists and dopamine receptors: their relevance to the treatment of Parkinson’s disease. International Workshop on Parkinson’s disease, Igls, AustriaGoogle Scholar
  7. Fazio C, Agnoli A, Casacchia M, Reitano M, Ruggieri S, Barba C (1972) Treatment of Parkinson’s disease with L-Dopa and an association L-Dopa plus a Dopa decarboxylase inhibitor. Z Neurol 202: 347–355PubMedCrossRefGoogle Scholar
  8. Goodwin-Austen RB, Twomey JA, Hanks G, Higgins J (1980) Oxpentiphylline in Parkinson’s disease. J Neurol Neurosurg Psychiatry 43: 360–364CrossRefGoogle Scholar
  9. Hyttel J (1978) Effects of neuroletpics on 3H-haloperidol and 3H-cis-z-flupentixol binding and on adenyl cyclase activity in vitro. Life Sci 23: 551–556PubMedCrossRefGoogle Scholar
  10. Kartzinel R, Shoulson I, Calne DB (1976a) Studies with bromocriptine. II Double blind comparison with L-Dopa in idiopathic parkinsonism. Neurology (Minneap) 26: 511–513Google Scholar
  11. Kartzinel R, Shoulson I, Calne DB (1976b) Studies with bromocriptine. III Concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology (Minneap) 26: 741–743Google Scholar
  12. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96PubMedCrossRefGoogle Scholar
  13. Lieberman A, Kupersmith M, Neophytides A, Casson I, Durso R, Hoo Foo S, Khayali M, Bear G, Goldstein M (1980) Long-term efficacy of bromocriptine in Parkinson’s disease. Neurology (NY) 30: 518–523Google Scholar
  14. Lieberman A, Goldstein M, Gopinathan G, Leibowitz M, Neophytides A, Walker R, Hiesiger E, Nelson J (1982) Further studies with pergolide in Parkinson’s disease. Neurology (NY) 32: 1181–1184Google Scholar
  15. Lieberman A, Gopinathan G, Neophytides A, Leibowitz M, Walker R, Hiesiger E (1983) Bromocriptine and lisuride in Parkinson’s disease. Ann Neurol 13: 44–47PubMedCrossRefGoogle Scholar
  16. McGeer PL, Boulding JE, Gibson WC, Foulkes RG (1961) Drug induced extrapiramidal reactions. JAMA 177: 665–670PubMedCrossRefGoogle Scholar
  17. Narabayashi M, Chida T, Kondo T (1979) Analysis of two factors influencing involuntary movements: psychological stress effect and motor effect. In: Poirier LJ, Sourkes TL, Bedard PJ (eds) Advances in neurology, vol 24. Raven, New York, pp 361–372Google Scholar
  18. Parkes JD, Schachter N, Marsden CD, Smith B, Wilson A (1981) Lisuride in parkinsonism. Ann Neurol 9: 48–52PubMedCrossRefGoogle Scholar
  19. Pletscher A (1976) Biochemical and pharmacological aspects of Parkinson’s syndrome: a short review: In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Roche, Basel, pp 21–36Google Scholar
  20. Poirier LJ, Filion M, Larochelle L, Péchadre JC (1976) Physiopathology of tremor and rigidity. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Roche, Basel, pp 217–235Google Scholar
  21. Price P, Parkes JD, Marsden CD (1978) Tiapride in Parkinson’s disease. Lancet 1106Google Scholar
  22. Rinne UK, Rinne JK, Rinne JO, Laakso K, Tenovuo O (1982) Neurotransmitters and neuropeptides in the parkinsonian brain. In: Integrative Neurohumoral Mechanisms. Physiological and clinical aspects, Budapest, 24–27 MarchGoogle Scholar
  23. Siegfrid J (1976) The treatment of parkinsonian tremor. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Roche, Basel, pp 319–327Google Scholar
  24. Spano PF, Govoni S, Trabucchi M (1978) Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. In: Roberts PJ, Woodruff GN, Iversen LL (eds) Advances in biochemical psychopharmacology. Raven, New York, pp 105–115Google Scholar
  25. Teravainen H, Evarts E, Calne D (1979) Effects of kinesthetic inputs on parkinsonism tremor. In: Poirier LJ, Sourkes TL, Bedard PJ (eds) Advances in neurology, vol 24. Raven, New York, pp 161–174Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • S. Ruggieri
  • A. Denaro
  • M. Baldassarre
  • F. Stocchi
  • A. Agnoli

There are no affiliations available

Personalised recommendations